Grail's 4-year, $8 billion saga draws to a close this month

Illumina's board agreed spin off cancer test subsidiary Grail, with shares distributed on June 24

June 11, 2024 Check out STAT+

Sponsored By

Our apologies for the incomplete edition earlier this morning. Here's the full lineup of our latest coverage:

Grail STAT+ | Illumina board agrees to spin off Grail, as divestment plans proceed It's the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. By Jason Mast STAT+ | With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment With interest rising in antibody-drug conjugates, Corbus reports at ASCO that its candidate "seems to be clinically effective in bladder cancer." By Adam Feuerstein STAT+ | Stephen Quake on the Chan Zuckerberg quest to cure, prevent, or manage all diseases by 2100 As head of science for the Chan Zuckerberg Initiative, Quake is trying to get the scientific community to work toward a hugely ambitious goal. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser